Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
This collaboration turns kitting into a strategic advantage for sponsors and sites
Diversifying its portfolio to include late-phase antiviral agent
Subscribe To Our Newsletter & Stay Updated